# Estimation Study to Assess the Effect of Severe Renal Impairment and End-stage Renal Disease Hemodialysis on the Pharmacokinetics of Evolocumab

> **NCT02275156** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 18 (actual)

## Conditions studied

- Hyperlipidemia
- Mixed Dyslipidemia

## Interventions

- **BIOLOGICAL:** Evolocumab

## Key facts

- **NCT ID:** NCT02275156
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08-19
- **Primary completion:** 2014-12-19
- **Final completion:** 2014-12-19
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2022-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02275156

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02275156, "Estimation Study to Assess the Effect of Severe Renal Impairment and End-stage Renal Disease Hemodialysis on the Pharmacokinetics of Evolocumab". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02275156. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*